DBV Fundamental Analysis - DBV TECHNOLOGIES SA

Fundamental Rating

Taking everything into account, DBV scores 3 out of 10 in our fundamental rating. DBV was compared to 82 industry peers in the Biotechnology industry. DBV may be in some trouble as it scores bad on both profitability and health. DBV is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year DBV has reported negative net income.

In the past year DBV has reported a negative cash flow from operations.

DBV had negative earnings in each of the past 5 years.

DBV had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -86.01%, DBV is doing worse than 75.61% of the companies in the same industry.

With a Return On Equity value of -143.02%, DBV is not doing good in the industry: 62.20% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
ROA	-86.01%
ROE	-143.02%
ROIC	N/A

ROA(3y)-83.86%

ROA(5y)-75.45%

ROE(3y)-174.58%

ROE(5y)-140.1%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Gross Margin of DBV (91.34%) is better than 84.15% of its industry peers.

In the last couple of years the Gross Margin of DBV has declined.

The Profit Margin and Operating Margin are not available for DBV so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	91.34%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-2.75%

GM growth 5Y-2.02%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

DBV does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, DBV has more shares outstanding

DBV has more shares outstanding than it did 5 years ago.

The debt/assets ratio for DBV is higher compared to a year ago.

2.2 Solvency

DBV has an Altman-Z score of -1.95. This is a bad value and indicates that DBV is not financially healthy and even has some risk of bankruptcy.

DBV has a worse Altman-Z score (-1.95) than 65.85% of its industry peers.

DBV has a Debt/Equity ratio of 0.08. This is a healthy value indicating a solid balance between debt and equity.

DBV has a Debt to Equity ratio (0.08) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0.08
Debt/FCF	N/A
Altman-Z	-1.95

ROIC/WACCN/A

WACC7.88%

2.3 Liquidity

DBV has a Current Ratio of 2.47. This indicates that DBV is financially healthy and has no problem in meeting its short term obligations.

With a Current ratio value of 2.47, DBV perfoms like the industry average, outperforming 50.00% of the companies in the same industry.

DBV has a Quick Ratio of 2.47. This indicates that DBV is financially healthy and has no problem in meeting its short term obligations.

Looking at the Quick ratio, with a value of 2.47, DBV is in line with its industry, outperforming 56.10% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	2.47
Quick Ratio	2.47

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

DBV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 43.66%, which is quite impressive.

Looking at the last year, DBV shows a very strong growth in Revenue. The Revenue has grown by 224.69%.

Measured over the past years, DBV shows a small growth in Revenue. The Revenue has been growing by 0.50% on average per year.

EPS 1Y (TTM)43.66%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%N/A

Revenue 1Y (TTM)224.69%

Revenue growth 3Y11.73%

Revenue growth 5Y0.5%

Sales Q2Q%N/A

3.2 Future

DBV is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.26% yearly.

The Revenue is expected to grow by 75.93% on average over the next years. This is a very strong growth

EPS Next Y-36.93%

EPS Next 2Y-15.64%

EPS Next 3Y22.79%

EPS Next 5Y16.26%

Revenue Next Year-55.09%

Revenue Next 2Y271.45%

Revenue Next 3Y438.04%

Revenue Next 5Y75.93%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

DBV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DBV. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

DBV's earnings are expected to grow with 22.79% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-15.64%

EPS Next 3Y22.79%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for DBV!.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

DBV TECHNOLOGIES SA

EPA:DBV (12/22/2025, 3:36:42 PM)

3.5

-0.1 (-2.78%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)10-28 2025-10-28/amc

Earnings (Next)03-23 2026-03-23/amc

Inst Owners61.98%

Inst Owner ChangeN/A

Ins Owners0.11%

Ins Owner ChangeN/A

Market Cap125.82M

Revenue(TTM)15.73M

Net Income(TTM)-123.00M

Analysts80

Price Target5.13 (46.57%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)29.41%

PT rev (3m)29.41%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)-5.23%

EPS NY rev (3m)0.66%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)0%

Revenue NY rev (1m)1.37%

Revenue NY rev (3m)1.37%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	38.78
P/FCF	N/A
P/OCF	N/A
P/B	1.71
P/tB	1.71
EV/EBITDA	N/A

EPS(TTM)-0.65

EYN/A

EPS(NY)-0.87

Fwd EYN/A

FCF(TTM)-2.07

FCFYN/A

OCF(TTM)-2.07

OCFYN/A

SpS0.09

BVpS2.04

TBVpS2.04

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-86.01%
ROE	-143.02%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	91.34%
FCFM	N/A

ROA(3y)-83.86%

ROA(5y)-75.45%

ROE(3y)-174.58%

ROE(5y)-140.1%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-2.75%

GM growth 5Y-2.02%

F-Score2

Asset Turnover0.03

Health

		Industry Rank	Sector Rank
Debt/Equity	0.08
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	41.89%
Cap/Sales	8.16%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.47
Quick Ratio	2.47
Altman-Z	-1.95

F-Score2

WACC7.88%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)25.42%

Cap/Sales(5y)23.37%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)43.66%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%N/A

EPS Next Y-36.93%

EPS Next 2Y-15.64%

EPS Next 3Y22.79%

EPS Next 5Y16.26%

Revenue 1Y (TTM)224.69%

Revenue growth 3Y11.73%

Revenue growth 5Y0.5%

Sales Q2Q%N/A

Revenue Next Year-55.09%

Revenue Next 2Y271.45%

Revenue Next 3Y438.04%

Revenue Next 5Y75.93%

EBIT growth 1Y-32.61%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year11.6%

EBIT Next 3Y16.74%

EBIT Next 5YN/A

FCF growth 1Y1.33%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y0.93%

OCF growth 3YN/A

OCF growth 5YN/A

DBV TECHNOLOGIES SA / DBV.PA FAQ

What is the fundamental rating for DBV stock?

ChartMill assigns a fundamental rating of 3 / 10 to DBV.PA.

Can you provide the valuation status for DBV TECHNOLOGIES SA?

ChartMill assigns a valuation rating of 1 / 10 to DBV TECHNOLOGIES SA (DBV.PA). This can be considered as Overvalued.

What is the profitability of DBV stock?

DBV TECHNOLOGIES SA (DBV.PA) has a profitability rating of 1 / 10.

What is the expected EPS growth for DBV TECHNOLOGIES SA (DBV.PA) stock?

The Earnings per Share (EPS) of DBV TECHNOLOGIES SA (DBV.PA) is expected to decline by -36.93% in the next year.

DBV TECHNOLOGIES SA (DBV.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

DBV TECHNOLOGIES SA / DBV.PA FAQ

What is the fundamental rating for DBV stock?

Can you provide the valuation status for DBV TECHNOLOGIES SA?

What is the profitability of DBV stock?

What is the expected EPS growth for DBV TECHNOLOGIES SA (DBV.PA) stock?